(1) Background: It is relevant to find new diagnostic biomarkers for endometrial cancer. This study aimed to investigate whether PDGF-AB, PDGF-BB, TGF-α, EGF and ANG-2 could be considered new useful markers for diagnosis and survival of endometrial cancer. (2) Methods: A total of 93 women diagnosed with endometrial cancer (EC) and 66 patients with non-cancerous endometrial lesions (NCEL) were included in this study. (3) Results: Median serum levels of PDGF-AB, PDGF-BB, TGF-α, EGF and ANG-2 were significantly higher in the EC group compared to the NCEL group (for PDGF-AB, PDGF-BB, TGF-α and ANG-2,p= 0.0000; for EGF,p= 0.0186). The cut-off level of PDGF-AB was set at 127.69 pg/mL with a sensitivity of 87.1% and a specificity of 66.67% (AUC = 0.78,p< 0.000001). The cut-off level of PDGF-BB was set at 207.86 ng/L with a sensitivity of 82.8% and a specificity of 75.76% (AUC = 0.85,p< 0.000001). The cut-off level of TGF-α was set at 33.85 ng/L with a sensitivity of 82.8% and a specificity of 75.76% (AUC = 0.82,p< 0.000001). The cut-off level of EGF was set at 934.76 pg/mL with a sensitivity of 83.87% and a specificity of 28.79% (AUC = 0.61,p= 0.018472). The cut-off level of ANG-2 was set at 3120.68 pg/mL with a sensitivity of 72.04% and a specificity of 93.94% (AUC = 0.87,p< 0.000001). (4) Conlusion: It was concluded that all the proteins studied could be potential diagnostic markers in endometrial cancer.
(1) 背景:寻找子宫内膜癌的新型诊断生物标志物具有重要意义。本研究旨在探讨PDGF-AB、PDGF-BB、TGF-α、EGF和ANG-2是否可作为子宫内膜癌诊断及预后评估的新型有效标志物。(2) 方法:本研究共纳入93例子宫内膜癌(EC)患者及66例非癌性子宫内膜病变(NCEL)患者。(3) 结果:与NCEL组相比,EC组患者血清PDGF-AB、PDGF-BB、TGF-α、EGF和ANG-2的中位水平均显著升高(PDGF-AB、PDGF-BB、TGF-α和ANG-2的p=0.0000;EGF的p=0.0186)。PDGF-AB的截断值设定为127.69 pg/mL,敏感度为87.1%,特异度为66.67%(AUC=0.78,p<0.000001);PDGF-BB的截断值为207.86 ng/L,敏感度82.8%,特异度75.76%(AUC=0.85,p<0.000001);TGF-α的截断值为33.85 ng/L,敏感度82.8%,特异度75.76%(AUC=0.82,p<0.000001);EGF的截断值为934.76 pg/mL,敏感度83.87%,特异度28.79%(AUC=0.61,p=0.018472);ANG-2的截断值为3120.68 pg/mL,敏感度72.04%,特异度93.94%(AUC=0.87,p<0.000001)。(4) 结论:研究表明所有检测蛋白均可能成为子宫内膜癌的潜在诊断标志物。